|
|
|
| Therapeutic effect of goserelin combined with mifepristone for treating patients with uterine fibroids and its influence on their levels of serum sex hormones, transforming growth factor β1 and tumor specific growth factor and their endometrium |
| 1. The Air Force Hospital of Eastern Theater of PLA, Nanjing, Jiangsu Province, 210002; 2. The Second Affiliated Hospital of Air Force Medical University (Tangdu Hospital), Xian, Shanxi Province; 3. Nanjing Yuhuatai District Yuhua Community Health Service Center, Nanjing, Jiangsu Province |
|
|
|
|
Abstract To investigate the efficacy of goserelin combined with mifepristone for treating patients with uterine fibroids, and to study its influence on the levels of serum sex hormones, transforming growth factor β1 (TGF-β1) and tumor specific growth factor(TSGF) of the patients. Methods: A total of 160 patients with uterine fibroids admitted to hospital were collected and randomly divided into two groups from May 2022 to October 2023. 80 patients in the control group received treatment of mifepristone for 6 months continuously, and 80 patients in the observation group received treatment of goserelin combined with mifepristone for 6 months continuously. The clinical therapeutic effect and the levels of sex hormones, TGF- β 1 and TSGF, and the endometrial thickness of the patients before and after treatment were compared between the two groups. Results: The total effective rate (91.3%) of the patients in the observation group was significantly higher than that (80.0%) of the patients in the control group. The levels of progesterone (3.12±1.05 μmol/L), testosterone (0.89±0.27 μmol/L), prolactin (12.01±3.41 μg/L), TGF-β1 (10.98±2.59 ng/L) and TSGF (27.86±7.84μmol/L), and the values of uterine volume (176.42±94.51 cm3), fibroid volume (28.09±9.51 cm3) and endometrial thickness (0.87±0.05 cm) of the patients in the observation group were significantly lower than those (4.67±1.87μmol/L, 1.96±0.89μmol/L, 15.42±3.98μg/L, 12.43±2.76 ng/L, 34.72±9.85μmol/L, 209.88±98.75 cm3, 32.43±9.84 cm3 and 0.94±0.09 cm) of the patients in the control group (all P<0.05). There was no significant difference in the adverse reactions rate (18.8% vs. 15.0%) of the patients between the two groups (P>0.05). Conclusion: Both mifepristone and goserelin has the effect for treating the patients with uterine fibroids, but goserelin combined with mifepristone has better effect, and which can regulate the sex hormones levels, reduce the TGF- β1 and TSGF levels, and decrease the uterus volume, fibroid volume and endometrial thickness of the patients, and without increasing the adverse reactions.
|
|
|
|
|
|
|
|
|
